Drug Trial Radar · NCT06780137
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
327
Planned (sponsor's estimate)
Start
Feb 27, 2025
Primary completion
Feb 15, 2029
Study completion Feb 15, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Jan 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment. The goals of this study are to learn: * If gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab are safe and well tolerated * If people who receive gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab have their SCLC get smaller or go away
Conditions
- Small Cell Lung Cancer
Interventions
GocatamigBiological
IV infusion
Ifinatamab Deruxtecan (I-DXd)Biological
IV infusion
DurvalumabBiological
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 44 months
- Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 3 weeks
- Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 44 months
- Part 1: Objective Response Rate (ORR)Time frame: Up to approximately 44 months
Locations
48 sites in 12 countries. Site status is shown where the registry gives one.
University of Colorado Anschutz Medical Campus ( Site 1110)
Aurora, Colorado · Recruiting
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111)
Miami, Florida · Recruiting
University of Chicago ( Site 1108)
Chicago, Illinois · Recruiting
Dana Farber Cancer Institute ( Site 1105)
Boston, Massachusetts · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103)
Hackensack, New Jersey · Recruiting
Roswell Park Cancer Institute ( Site 1107)
Buffalo, New York · Recruiting
Providence Portland Medical Center ( Site 1101)
Portland, Oregon · Recruiting
Sarah Cannon Research Institute ( Site 7001)
Nashville, Tennessee · Recruiting
Medical College of Wisconsin ( Site 1112)
Milwaukee, Wisconsin · Recruiting
Hospital Universitario Austral ( Site 2204)
Pilar, Buenos Aires, Argentina · Recruiting
Sanatorio Parque ( Site 2203)
Rosario, Santa Fe Province, Argentina · Recruiting
Princess Alexandra Hospital ( Site 5300)
Woolloongabba, Queensland, Australia · Recruiting
Monash Health ( Site 5301)
Clayton, Victoria, Australia · Recruiting
FALP ( Site 2100)
Santiago, Region M. de Santiago, Chile · Recruiting
Pontificia Universidad Catolica de Chile ( Site 2102)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 2101)
Santiago, Region M. de Santiago, Chile · Recruiting
Beijing Cancer Hospital ( Site 5401)
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital ( Site 5413)
Fuzhou, Fujian, China · Recruiting
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology ( Site 5403)
Nanjing, Jiangsu, China · Recruiting
Shanghai Chest Hospital ( Site 5400)
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital ( Site 5405)
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital of Sichuan University ( Site 5416)
Chengdu, Sichuan, China · Recruiting
The First Affiliated Hospital, Zhejiang University ( Site 5404)
Hangzhou, Zhejiang, China · Recruiting
Rambam Health Care Campus ( Site 3202)
Haifa, Israel · Active not recruiting
Shaare Zedek Medical Center ( Site 3200)
Jerusalem, Israel · Recruiting
Rabin Medical Center ( Site 3203)
Petah Tikva, Israel · Recruiting
Sheba Medical Center ( Site 3201)
Ramat Gan, Israel · Recruiting
Aichi Cancer Center ( Site 5000)
Nagoya, Aichi-ken, Japan · Recruiting
National Cancer Center Hospital East ( Site 5001)
Kashiwa, Chiba, Japan · Recruiting
Kansai Medical University Hospital ( Site 5004)
Hirakata, Osaka, Japan · Recruiting
Cancer Institute Hospital of JFCR ( Site 5002)
Koto, Tokyo, Japan · Recruiting
Seoul National University Hospital ( Site 5100)
Seoul, South Korea · Recruiting
Severance Hospital, Yonsei University Health System ( Site 5102)
Seoul, South Korea · Recruiting
Samsung Medical Center ( Site 5101)
Seoul, South Korea · Recruiting
Hospital Universitari Vall d'Hebron ( Site 3311)
Barcelona, Spain · Recruiting
Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 3315)
Madrid, Spain · Recruiting
Hospital Universitario HM Sanchinarro ( Site 3313)
Madrid, Spain · Recruiting
Hospital Universitario Virgen de la Victoria ( Site 3312)
Málaga, Spain · Recruiting
HOSPITAL CLÍNIC DE BARCELONA ( Site 3310)
Eixample, Barcelona, Spain · Recruiting
Institut Català d'Oncologia - L'Hospitalet ( Site 3317)
L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.